In 2021, the company acquired GW Pharmaceuticals for $7.2bn, gaining the seizure medication Epidiolex (cannabidiol). In February 2024, it licensed a KRAS inhibitor programme from UK-based Redx ...

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion takeover by Jazz Pharma.

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter ... was the centerpiece of its $7.2 billion buyout of GW Pharmaceuticals in 2021. As one analyst noted ...

“It’s a huge breakthrough for the concept of cannabinoids as medicines,” says Justin Gover, CEO of manufacturer GW Pharmaceuticals. Next, the company is exploring how effective CBD and other ...

Jazz Pharmaceuticals, a Zacks Rank #1 (Strong Buy), is a specialty biopharmaceutical company that identifies, develops, and ...

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range ...

Assess today's live GW Pharmaceuticals PLC (GWPRF) share price, performance and insights using our live OTC Markets: GWPRF stock exchange data. Analyse the historical data and GW Pharmaceuticals PLC ...

GW Pharmaceuticals is a cutting-edge UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and the development of ...